GPP
UNCY icon

Great Point Partners’s Unicycive Therapeutics UNCY Stock Holding History

Great Point Partners’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-796,558
Closed -$5.24M – 53
2026
Q1 		$5.24M Hold
796,558
– – 1.2% 30
2025
Q4 		$4.6M Hold
796,558
– – 1.49% 24
2025
Q3 		$3.47M Hold
796,558
– – 1.43% 25
2025
Q2 		$3.8M Sell
796,558
-301,442
-27% -$1.86M 2.47% 15
2025
Q1 		$6.31M Hold
1,098,000
– – 3.34% 14
2024
Q4 		$8.72M Buy
1,098,000
+242,100
+28% +$1.34M 4.11% 11
2024
Q3 		$3.49M Buy
+855,900
New +$3.44M 1.03% 26

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Great Point Partners's UNCY Position: Q2 2026 in Review

Great Point Partners sold out of Unicycive Therapeutics (UNCY) in Q2 2026, closing a stake of 796,558 shares — an estimated $5.24M sold.

Great Point Partners first reported a position in UNCY in Q3 2024 and held it in 7 quarters. The position peaked at $8.72M in Q4 2024. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Great Point Partners reported no remaining Unicycive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Great Point Partners sold 796,558 Unicycive Therapeutics shares in Q2 2026, an estimated $5.24M.
  • Great Point Partners first reported a position in Unicycive Therapeutics in Q3 2024 and held it in 7 quarters.
  • Great Point Partners's Unicycive Therapeutics position peaked at $8.72M in Q4 2024.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.